Kaliumklorid Braun (Potassium Chloride)

After infusion, potassium chloride dissociates into potassium ions and chloride. The potassium ions increase extracellular potassium concentration, which then moves into cells via the Na⁺/K⁺‑ATPase pump, restoring the normal electrochemical gradient needed for nerve impulse transmission, muscle contraction and proper cardiac rhythm.

The dose of Kaliumklorid Braun is individualized by the prescribing clinician based on the patient’s serum potassium level, renal function, and overall clinical condition. Healthcare professionals determine the concentration, infusion rate, and total amount required for safe correction of potassium deficiency.

Safety data for Kaliumklorid Braun in pregnancy and lactation are limited. The decision to use it during pregnancy or while breastfeeding should be made by a qualified healthcare provider, weighing the potential benefits for the mother against any possible risks to the fetus or infant.

To order Kaliumklorid Braun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Kaliumklorid Braun is an intravenous formulation, offering rapid correction of potassium deficits, whereas oral potassium chloride tablets or liquids provide slower, more gradual replenishment. IV delivery is preferred in acute settings, severe hypokalemia, or when oral intake is not possible, while oral forms are used for maintenance therapy.

Kaliumklorid Braun should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the solution, and keep it in the original packaging until use. Before administration, inspect for particulate matter or discoloration and follow aseptic techniques for preparation.

Kaliumklorid Braun is administered by intravenous infusion. The prescribing clinician determines the infusion rate, which is usually controlled to avoid rapid increases in serum potassium. Infusion should be performed using a calibrated pump or drip set, with continuous monitoring of the patient’s cardiac rhythm and serum potassium levels.

The most serious risks include severe hyperkalemia leading to life‑threatening cardiac arrhythmias such as ventricular fibrillation, cardiac arrest, and rare anaphylactic reactions. Prompt recognition of rising potassium levels and immediate medical intervention are essential to prevent these outcomes.

Kaliumklorid Braun is contraindicated in patients with existing hyperkalemia, severe renal failure where potassium excretion is impaired, and in individuals with known hypersensitivity to potassium chloride. It should also be used with caution in patients receiving other potassium‑raising agents or those with unstable cardiac conditions.